

RECEIVED  
CENTRAL FAX CENTER

EPR 2.6

OFFICIAL

**FACSIMILE COVER SHEET**

GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, Research Triangle Park, NC 27709

ATTENTION: EXAMINER  
YELENA G. GAKH  
ART UNIT 1743

Company/Division: USPTO

Phone:

Fax: 703/872-9306

From: Joyce Hartnett (on behalf of  
Robert J. Smith)

Company/Division: GlaxoSmithKline

Phone: 919/483-7776

Fax: 919/483-5730

Date: February 26, 2004

Pages to follow: 12

*This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, or exempt from disclosure under applicable federal or state law. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited.*

**ART UNIT # 1743 - RESPONSE TO NOTICE OF NON-COMPLIANT  
AMENDMENT (37 CFR 1.121)**

Docket No.: PU3682USW

Serial No.: 10/009,704

Filing Date: 10/29/2001

Examiner: Yelena G. Gakh

Group Art Unit: 1743


Invention: *METHOD AND SYSTEM FOR DETECTING TRACE MATERIALS IN  
CRYOGENIC LIQUIDS*

**Attachments:**

- 1.) Certificate of Transmission of Facsimile
- 2.) Amendment Transmittal Letter
- 3.) Response
- 4.) Missing Remarks

|   |                           |                            |                        |
|---|---------------------------|----------------------------|------------------------|
| <b>CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)</b>  |                           |                            | Docket No.             |
| Applicant(s): WALKER, Dwight Sherrod, et. al.   |                           |                            | PU3682USW              |
| Serial No.<br>10/009,704  | Filing Date<br>10/29/2001 | Examiner<br>Yelena G. Gakh | Group Art Unit<br>1743 |
| Invention: METHOD AND SYSTEM FOR DETECTING TRACE MATERIALS IN CRYOGENIC LIQUIDS   |                           |                            |                        |
| <p>I hereby certify that this <u>Amendment Transmittal Letter, Response and Missing Remarks</u><br/>(Identify type of correspondence)</p> <p>is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-872-9306</u>)</p> <p>on <u>February 26, 2004</u><br/>(Date)</p> <p><u>Joyce Hartnett</u><br/>(Typed or Printed Name of Person Signing Certificate)</p> <p><u>Joyce Hartnett</u><br/>(Signature)</p> |                           |                            |                        |

P18/REV01

|  |                                     |                                   |  |                                |                   |
|--|-------------------------------------|-----------------------------------|--|--------------------------------|-------------------|
| <b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>   |                                     |                                   |  | Docket No.<br><b>PU3682USW</b> |                   |
| Applicant(s): <b>WALKER, Dwight Sherrod, et. al.</b>   |                                     |                                   |  |                                |                   |
| Serial No.<br><b>10/009,704</b>  | Filing Date<br><b>10/29/2001</b>    | Examiner<br><b>Yelena G. Gakh</b> |  | Group Art Unit<br><b>1743</b>  |                   |
| Invention: <b>METHOD AND SYSTEM FOR DETECTING TRACE MATERIALS IN CRYOGENIC LIQUIDS</b>   |                                     |                                   |  |                                |                   |
| <b><u>TO THE COMMISSIONER FOR PATENTS:</u></b>   |                                     |                                   |  |                                |                   |
| Transmitted herewith is an amendment in the above-identified application.  |                                     |                                   |  |                                |                   |
| The fee has been calculated and is transmitted as shown below.   |                                     |                                   |  |                                |                   |
| <b>CLAIMS AS AMENDED</b>   |                                     |                                   |  |                                |                   |
|  | CLAIMS REMAINING<br>AFTER AMENDMENT | HIGHEST #<br>PREV. PAID FOR       | NUMBER EXTRA<br>CLAIMS PRESENT   | RATE                           | ADDITIONAL<br>FEE |
| TOTAL CLAIMS   | 25 -                                | 29 =                              | 0 x  | \$18.00                        | \$0.00            |
| INDEP. CLAIMS  | 4 -                                 | 4 =                               | 0 x  | \$86.00                        | \$0.00            |
| Multiple Dependent Claims (check if applicable) <input type="checkbox"/>   |                                     |                                   |  |                                | \$0.00            |
| <b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>   |                                     |                                   |  |                                | <b>\$0.00</b>     |
| <p><input checked="" type="checkbox"/> No additional fee is required for amendment.</p> <p><input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____</p> <p><input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.</p> <p><input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>07-1392</b></p> <p><input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.</p> <p><input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</p> |                                     |                                   |  |                                |                   |
| <br>_____<br>Signature  |                                     |                                   | Dated: <i>February 26, 2004</i>  |                                |                   |
| <b>Robert J. Smith</b><br><b>Registration No.: 40,820</b><br><b>GlaxoSmithKline</b><br><b>Corporate Intellectual Property</b><br><b>Five Moore Drive</b><br><b>Research Triangle Park, NC 27709</b><br><b>Tel: 919/483-9616 Fax: 919/483-7988</b>  |                                     |                                   | <div style="border: 1px solid black; padding: 5px;"> <p>I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37C.F.R. 1.8 and is addressed to the for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p> <p style="text-align: center;">_____<br/>Signature of Person Mailing Correspondence</p> <p style="text-align: center;">_____<br/>Typed or Printed Name of Person Mailing Correspondence</p> </div> |                                |                   |
| CC:  |                                     |                                   |  |                                |                   |

P11LARGE/REV08

RECEIVED  
CENTRAL FAX CENTER

FEB 26 2004

Attorney Docket No. PU 3682 USw

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

OFFICIAL

In re Application of Walker et al.

U.S. Serial No.: 10/009,704

Group Art Unit: 1743

U.S. Filing Date: October 29, 2001

Examiner: Y. Gakh

Title: *Method and System for Detecting Trace Materials  
In Cryogenic Liquids*

**RESPONSE**

Commissioner for Patents  
Washington D.C. 20231

Sir:


This is filed in response to the Office Action dated January 29, 2004 reporting a Notice of Non-Compliant Amendment. More specifically, the Office alleges that the remarks from Applicants' response of December 22, 2003 are missing.

In response, a copy of the Remarks section of the above amendment is submitted herewith.

U.S. Serial No. 10/203,726  
Filed: August 13, 2002  
Page 2 of 2

Respectfully submitted,

Date: February 26, 2004



Robert J. Smith  
Reg. No. 40,820  
Attorney for Applicants

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, NC 27709-3398  
Direct Phone (919) 483-9616  
Facsimile (919) 483-7988